KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases.

$13.45  +1.24 (10.16%)
As of 12/07/2021 14:04:06 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  Bermuda
IPO date:  05/24/2018
Outstanding shares:  33,887,757
Average volume:  287,546
Market cap:   $401,569,920
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    G5269C101
ISIN:        BMG5269C1010
Sedol:      BD0MGM0
Valuation   (See tab for details)
PE ratio:   -5.74
PB ratio:   3.93
PS ratio:   20.28
Return on equity:   -81.87%
Net income %:   -885.14%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy